In the FIDELIO-DKD trial, finerenone treatment lowered the risk of chronic kidney disease (CKD) progression and of cardiovascular (CV) events in patients with type 2 diabetes and advanced CKD . There were no differences in treatment effect depending on pre-existing CVD status. The results demonstrated benefits of finerenone for both primary and secondary CV prevention.
Prof. Gerasimos Filippatos (National and Kapodistrian University of Athens, Greece) shared the results of the phase 3 FIDELIO-DKD trial (NCT02540993), which was designed to evaluate the efficacy of finerenone in slowing CKD progression and reducing CV events in patients diagnosed with advanced CKD and type 2 diabetes; these results were simultaneously published in the New England Journal of Medicine [1,2]. Finerenone is a non-steroidal, selective mineralocorticoid receptor a...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Mavacamten effective in obstructive hypertrophic cardiomyopathy Next Article
Sotatercept: potential new treatment option for PAH »